NASDAQ:XBIT - XBiotech Stock Price, Forecast & News

XBiotech trades on the NASDAQ under the ticker symbol "XBIT."

XBiotech Inc (NASDAQ:XBIT) issued its earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.15) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.15). View XBiotech's Earnings History.

XBiotech is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for XBiotech.

1 equities research analysts have issued 1 year price objectives for XBiotech's shares. Their forecasts range from $28.00 to $28.00. On average, they anticipate XBiotech's share price to reach $28.00 in the next twelve months. This suggests a possible upside of 15.2% from the stock's current price. View Analyst Price Targets for XBiotech.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XBiotech in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for XBiotech.

Media stories about XBIT stock have trended somewhat positive recently, according to InfoTrie. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. XBiotech earned a media sentiment score of 0.7 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for XBiotech.

XBiotech saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 3,590,000 shares, an increase of 10.8% from the December 15th total of 3,240,000 shares. Based on an average daily volume of 311,500 shares, the short-interest ratio is currently 11.5 days. Currently, 20.2% of the company's shares are sold short. View XBiotech's Current Options Chain.

Some companies that are related to XBiotech include SAGE Therapeutics (SAGE), Blueprint Medicines (BPMC), FibroGen (FGEN), Mirati Therapeutics (MRTX), HUTCHISON CHINA/S (HCM), Evotec (EVTCY), Intercept Pharmaceuticals (ICPT), GW Pharmaceuticals PLC- (GWPH), Ultragenyx Pharmaceutical (RARE), Myokardia (MYOK), Deciphera Pharmaceuticals (DCPH), Taro Pharmaceutical Industries (TARO), PTC Therapeutics (PTCT), Axsome Therapeutics (AXSM) and Agios Pharmaceuticals (AGIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other XBiotech investors own include Zynerba Pharmaceuticals (ZYNE), Agile Therapeutics (AGRX), Fate Therapeutics (FATE), Amicus Therapeutics (FOLD), Karyopharm Therapeutics (KPTI), Tetraphase Pharmaceuticals (TTPH), TherapeuticsMD (TXMD), TransEnterix (TRXC), Ardelyx (ARDX) and Cidara Therapeutics (CDTX).

(XBIT) raised $76 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $18.00-$20.00 per share. WR Hambrecht + Co acted as the underwriter for the IPO.

XBiotech's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Silverleafe Capital Partners LLC (0.06%). Company insiders that own XBiotech stock include Fondation Rennes, Queena Han, W Thorpe Mckenzie and W Thorpe Mckenzie. View Institutional Ownership Trends for XBiotech.

XBIT stock was purchased by a variety of institutional investors in the last quarter, including Silverleafe Capital Partners LLC. Company insiders that have bought XBiotech stock in the last two years include Fondation Rennes and W Thorpe Mckenzie. View Insider Buying and Selling for XBiotech.

Shares of XBIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of XBIT stock can currently be purchased for approximately $24.30.

XBiotech has a market capitalization of $998.41 million. The biopharmaceutical company earns $-21,140,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. XBiotech employs 56 workers across the globe.View Additional Information About XBiotech.

The official website for XBiotech is http://www.xbiotech.com/.

XBiotech's mailing address is 5217 Winnebago Ln, AUSTIN TX, 78744. The biopharmaceutical company can be reached via phone at 512-386-2900 or via email at [email protected]